Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland

Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study

(2020) Mark A. Samaan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More

(2020) Benjamin Misselwitz et al.   DIGESTION

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis

(2020) Dana Lukin et al.   Clinical Gastroenterology and Hepatology

Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label

(2020) Sebastian Stefanovic et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

(2020) Marisa Iborra et al.   Scientific Reports

Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)

(2019) Valérie Pittet et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis

(2019) Fabrizio Bossa et al.   DIGESTIVE DISEASES AND SCIENCES

Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

(2018) Siddharth Singh et al.   Journal of Crohns & Colitis

Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study

(2018) Levente Parragi et al.   Journal of Crohns & Colitis

Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centers

(2018) Beatrice Orlandini et al.   Journal of Digestive Diseases

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician

(2018) Lawrence Blonde et al.   ADVANCES IN THERAPY

Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

(2017) Carlos Taxonera et al.   INFLAMMATORY BOWEL DISEASES

Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease

(2016) Lieven Pouillon et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis

(2016) Iris Detrez et al.   Journal of Crohns & Colitis

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study

(2016) Marta Maia Bosca-Watts et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis

(2016) Antonio Tursi et al.   Clinics and Research in Hepatology and Gastroenterology

Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis

(2016) M. Anthony Sofia et al.   Therapeutic Advances in Gastroenterology

Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease

(2016) Uri Kopylov et al.   Therapeutic Advances in Gastroenterology

Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis

(2016) Adrian D. Vickers et al.   PLoS One

High Rates of Smoking Especially in Female Crohn’s Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation—Data from the Swiss IBD Cohort Study

(2015) Luc Biedermann et al.   Journal of Crohns & Colitis

Where are we heading to in pharmacological IBD therapy?

(2015) Gerhard Rogler   PHARMACOLOGICAL RESEARCH

Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs

(2015) Kristian Thorlund et al.   Expert Review of Gastroenterology & Hepatology

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Cohort Profile: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)

(2008) V. Pittet et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY